%0 Journal Article %A Tsuyoshi Sekizuka %A Kentaro Itokawa %A Masumichi Saito %A Michitsugu Shimatani %A Shutoku Matsuyama %A Hideki Hasegawa %A Tomoya Saito %A Makoto Kuroda %A COVID-19 Genomic Surveillance Network in Japan (COG-JP) %T Genome Recombination between Delta and Alpha Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) %D 2021 %R 10.1101/2021.10.11.21264606 %J medRxiv %P 2021.10.11.21264606 %X Prominent genomic recombination has been observed between the Delta and Alpha variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolated from clinical specimens in Japan. It is necessary to intensively study such marked genetic variations and characterize the emerging variants after careful verification of their lineage and clade assignment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Grant-in-Aid from the Japan Agency for Medical Research and the Development Research Program on Emerging and Re-emerging Infectious Diseases (JP21fk0108103) and a grant from the Ministry of Health, Labor, and Welfare, Japan (19HA1001 and 20HA2007).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the National Institute of Infectious Diseases, Japan (Approval no. 1091). The ethics committee waived the requirement for written consent with respect to research on viral genome sequences.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available from GISAID and DNA Data Bank of Japan (DDBJ). Raw NGS sequencing reads have been deposited in the DNA Data Bank of Japan (DDBJ; accession number: DRA012825), as shown in the Table.  %U https://www.medrxiv.org/content/medrxiv/early/2021/10/14/2021.10.11.21264606.full.pdf